0001104659-22-053615.txt : 20220429
0001104659-22-053615.hdr.sgml : 20220429
20220429162200
ACCESSION NUMBER: 0001104659-22-053615
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210601
FILED AS OF DATE: 20220429
DATE AS OF CHANGE: 20220429
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROSENWALD LINDSAY A MD
CENTRAL INDEX KEY: 0000941841
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35366
FILM NUMBER: 22875897
MAIL ADDRESS:
STREET 1: 375 PARK AVE
CITY: NEW YORK
STATE: NY
ZIP: 10152
FORMER NAME:
FORMER CONFORMED NAME: ROSENWALD LINDSAY MD
DATE OF NAME CHANGE: 19950316
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fortress Biotech, Inc.
CENTRAL INDEX KEY: 0001429260
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205157386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
FORMER COMPANY:
FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC
DATE OF NAME CHANGE: 20080310
4
1
tm2213913-6_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-06-01
0
0001429260
Fortress Biotech, Inc.
FBIO
0000941841
ROSENWALD LINDSAY A MD
C/O FORTRESS BIOTECH, INC.
1111 KANE CONCOURSE SUITE 301
BAY HARBOR ISLAND
FL
33154
1
1
1
0
PRESIDENT, CEO & CHAIRMAN
COMMON STOCK, PAR VALUE $0.001
2021-06-01
4
A
0
1297
2.31
A
10408336
D
COMMON STOCK, PAR VALUE $0.001
2021-09-30
4
J
0
8133
0
A
10416469
D
COMMON STOCK, PAR VALUE $0.001
2021-11-16
4
J
0
4619
0
A
10421088
D
COMMON STOCK, PAR VALUE $0.001
2021-12-01
4
A
0
1250
2.42
A
10422338
D
COMMON STOCK, PAR VALUE $0.001
2022-01-01
4
A
0
1102986
0
A
11525324
D
Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period.
The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock.
The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock.
The reporting person was granted 1,102,986 restricted shares pursuant to the issuer's Long-Term Incentive Plan on January 1, 2022.
/s/ Samuel Berry, Attorney-in-Fact
2022-04-29